Research efforts are laser-focused on finding coronavirus treatments to save the most critically ill.
But what about everyone else?
A new clinical trial at Stanford University is part of an emerging movement to find COVID-19 medicines that can be given almost immediately after infection, before the virus gains a firm foothold in the body.
If effective, this strategy could ease the misery of the estimated 80% of patients who experience mild or moderate symptoms. Even more significantly, by targeting disease in its early stage, it could prevent progression to the severe and often fatal illness seen in 20 percent of cases. Community viral spread would be slowed.
Hopes are pinned on the Stanford outpatient trial of a compound called peginterferon lambda-1a. Already proven safe when tested against other illnesses, it shows early signs of efficacy against the COVID-19 virus in animals.
Stanford is recruiting newly-infected people in hopes of reaching 120 volunteers by Memorial Day….